Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
CYAD (Celyad Oncology SA) provides a centralized hub for tracking developments in clinical-stage cell therapies and immuno-oncology innovations. This resource aggregates essential updates including trial progress, regulatory milestones, and strategic partnerships critical for evaluating the company's position in cancer treatment research.
Investors and researchers will find curated press releases detailing CYAD's NKR-T cell programs, manufacturing advancements, and collaborative initiatives with institutions like Dartmouth College. The collection emphasizes factual reporting on phase transitions, financial disclosures, and operational updates without speculative commentary.
Content spans clinical trial authorizations, intellectual property developments, and executive leadership changes. Regular updates ensure stakeholders maintain current awareness of CYAD's progress in translating cell-based therapies from laboratory research to clinical applications.
Bookmark this page for streamlined access to verified CYAD developments. Combine periodic reviews with real-time monitoring for comprehensive analysis of the company's evolving role in advanced cancer treatment solutions.
Celyad Oncology (CYAD) reported a strategic shift in its business model, emphasizing the monetization of its cell therapy intellectual property and advancing R&D. A €6 million asset purchase agreement with Cellistic for its GMP-grade facility bolsters its cash runway. The company has discontinued the development of CYAD-101 due to delays and costs. Updates on the Phase 1 IMMUNICY-1 trial for CYAD-211 are anticipated by the year's end. Financially, as of September 30, 2022, Celyad holds €13.4 million in cash but projects insufficient funds beyond mid-2023 without additional capital.
Celyad Oncology (CYAD) has announced updates on its strategic business model and clinical programs. The company plans to enhance its intellectual property and R&D efforts, especially around its U.S. patents for allogeneic CAR T therapies. Notably, it has decided to discontinue the development of CYAD-101 for metastatic colorectal cancer due to financial and medical reviews, though no new safety issues were reported. In contrast, CYAD-211 continues in the Phase 1 trial, showing promising results in managing graft-versus-host disease. Clinical updates are expected by year-end.
Celyad Oncology has announced the sale of its Good Manufacturing Practice (GMP) cell therapy manufacturing operations to Cellistic for €6 million. The facility, located in Mont-Saint-Guibert, Belgium, comes with an experienced team of over 30 personnel. The transaction aims to streamline Celyad's focus on allogeneic therapies while leveraging Cellistic's expertise in iPSC-based cell therapies. The deal is anticipated to close in Q4 2022, providing Celyad with resources to continue its clinical programs until 2024.
Celyad Oncology announced ongoing enrollment in its Phase 1 dose-escalation trial for CYAD-211, targeting relapsed/refractory multiple myeloma. The FDA lifted the hold on CYAD-101 for metastatic colorectal cancer. The company reported a net loss of €14.1 million for H1 2022, an improvement from €14.9 million in H1 2021. Cash reserves stand at €14.4 million. Research and development expenses rose to €10.5 million due to increased IP costs. Celyad aims to enhance partnerships leveraging its extensive CAR T technology IP portfolio.
Celyad Oncology (CYAD) announced the FDA has lifted the clinical hold on its CYAD-101-002 (KEYNOTE-B79) Phase 1b trial, enabling the continuation of its investigation into allogeneic NKG2D CAR T cell therapy combined with KEYTRUDA for refractory metastatic colorectal cancer. The trial had been paused due to safety concerns following reports of fatalities. Celyad remains optimistic about the potential of CYAD-101 and its proprietary TIM technology.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced plans to report its first half 2022 financial and operating results on August 5, 2022. Following this release, management will host a conference call at 2 p.m. CEST to discuss the results and updates on recent progress and milestones.
The company is focused on CAR T therapies for cancer and has a pipeline of candidates for treating hematological malignancies and solid tumors. Detailed insights on its financial condition and ongoing trials, including the CYAD-101-002 trial, will be provided during the call.
Celyad Oncology SA (NASDAQ:CYAD) announced the appointment of Hilde Windels as Chairwoman of the Board of Directors, effective immediately. Windels has been on the board since May 2018 and has extensive experience in the life sciences sector. She replaces Michel Lussier, who becomes the Interim Chief Executive Officer following the resignation of Filippo Petti. Petti will assist during the transition until July 31, 2022. The company's strategy focuses on developing innovative CAR T therapies for cancer.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced that as of May 25, 2022, 350 registered shares will benefit from double voting rights. This change increases the total number of voting rights to 24,962,331. The company disclosed this in compliance with Belgian regulations regarding major shareholdings. Key figures include a total share capital of €78,584,224.33, with 20,225,581 shares having single voting rights and 2,368,375 shares having double voting rights.
Celyad Oncology SA (Brussels:CYAD) announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company will present virtually, with on-demand access starting at 7:00 a.m. EST on May 24, 2022. Celyad Oncology focuses on developing CAR T therapies for cancer, including both allogeneic and autologous candidates targeting hematological malignancies and solid tumors. The company, founded in 2007, received funding from the Walloon Region of Belgium to support its programs.
The financial update from Celyad Oncology (CYAD) highlights a cash position of €20.5 million ($22.9 million) and a net cash burn of €9.5 million ($10.6 million) for Q1 2022. The Phase 1 IMMUNICY-1 trial for CYAD-211 continues to enroll patients to evaluate its effectiveness against relapsed/refractory multiple myeloma. However, the CYAD-101-002 Phase 1b trial remains on clinical hold due to safety concerns, following reported fatalities. The company plans to release additional data on CYAD-211 in H2 2022 and expects its cash reserves to last until mid-2023.
FAQ
What is the market cap of CYAD (CYAD)?
